Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daly, P. A.
Right arrow Articles by Barton, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daly, P. A.
Right arrow Articles by Barton, D. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:549-553, 2003
© 2003 European Society for Medical Oncology

Original Paper

Predictive testing for BRCA1 and 2 mutations: a male contribution

P. A. Daly1,+, C. Nolan1, A. Green2, W. Ormiston1, N. Cody2, T. McDevitt2, B. O’hIci2, D. Byrne1, E. McDermott3, D. N. Carney4, N. O’Higgins3 and D. E. Barton2

1 Department of Haematology and Oncology, St James’s Hospital and Trinity College, Dublin; 2 National Centre for Medical Genetics and University College, Dublin; 3 St Vincent’s University Hospital and University College, Dublin; 4 Mater Misericordiae University Hospital and University College, Dublin, Ireland

Received 8 July 2002; revised 6 November 2002; accepted 28 November 2002

Background:

Management strategies for women carrying BRCA1 and 2 mutations are becoming clearer and predictive testing for a known family mutation is commonly undertaken. Implications for men are not as clear and they participate less frequently.

Patients and methods:

Twenty-six men from 10 extended families underwent predictive testing. Their motivation, reaction and outcome were studied. Subjects had appropriate pre- and post-test counselling. Informed consent was obtained before predictive testing for known deleterious mutations. DNA analysis followed standard procedures.

Results:

Eighteen tested positive and eight negative. Four had adverse psychological reactions and three reneged on their commitments to impart results. The spouse of another man had an adverse psychological reaction to the disclosure of his positive result. Two, already suffering from prostate cancer, were phenocopies and paternal lineage transmission was unexpectedly determined in another. Risk was removed from 33 offspring and confirmed for 56.

Conclusions:

Complex themes associated with genetic testing are confirmed and the spectrum extended. Men appear to understand the importance of participating in this process. Methods of avoiding adverse reactions merit further study along with other aspects of the process.

Key words: BRCA1, BRCA2, cancer genetics, predictive testing in men


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Qual Health ResHome page
L. d'Agincourt-Canning
Genetic Testing for Hereditary Breast and Ovarian Cancer: Responsibility and Choice
Qual Health Res, January 1, 2006; 16(1): 97 - 118.
[Abstract] [PDF]

Home page
 JCOHome page
A. Liede, B. Y. Karlan, and S. A. Narod
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
J. Clin. Oncol., February 15, 2004; 22(4): 735 - 742.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.